INTRODUCTION:

Prolegomenon:

Personalized pharmaceutical is a developing hone of pharmaceutical that employments an individual's hereditary profile to direct choices made in respect to the avoidance, determination, and treatment of malady¹. Information of a patient's hereditary profile can offer assistance specialists select the appropriate pharmaceutical or treatment and regulate it utilizing the appropriate measurements or regimen². Personalized pharmaceutical is being progressed through information from the Human Genome Extend³.

Definition:

The "one size fits all" approach to medication therapy, prevention, and diagnostics can be transformed into a tailored strategy with personalized medicine⁴. Furthermore, the notion that medicine would be administered in a way that disregards these variations cannot be more accurate than purchasing any old pair of shoes from the shoe store without first determining their size. The development of personalized medicine is greatly aided by genomics, which provides a very specific molecular window into our individual differences and enables the creation of personalized disease risk predictions that can assist individuals in selecting the best preventative strategy for them⁵ Instead of using a "one size fits all" approach to medication therapy, it also permits the possibility of choosing the appropriate drug at the appropriate⁶.

What Exactly Is It?:

The phrase "personalized medicine" has gained popularity recently, in part due to advancements like the Human Genome Project and in part because medications are rarely 100% safe and effective⁷. Many people think that these advancements will increase our ability to prevent and treat a variety of diseases by enabling the identification of subtypes of various diseases based on genetics in addition to other methods like histology⁸. Genetic information might be used, for instance, to ascertain if individuals with particular disease subtypes are more likely than others to respond to a given medication (both new and old)⁹. On the surface, it appears like everyone agrees on what personalized medicine means. However, a closer look at the current definitions of customized medicine shows significant differences amongst them.¹⁰

How it Works:

Genetic Data:

Analyzing a person’s genetic composition to determine how their genes affect their health, risk of disease, and reaction to therapies is a common practice in personalized medicine¹¹. To find DNA changes that could make a person more susceptible to certain diseases or alter how they react to drugs, this may entail genetic testing¹².

Customized Treatment Programs:

Healthcare professionals can create individualized treatment programs that are more efficient and possibly safer than generic treatments. based on this genetic information as well as additional variables including lifestyle decisions and environmental exposures¹³ For instance, some cancer treatments can target particular genetic alterations found in a patient’s tumor, improving results and reducing adverse effects¹⁴.

Strategies for Prevention:

Preventive measures based on each person’s particular risk factors are another focus of personalized medicine¹⁵. Healthcare professionals can suggest tailored therapies to lower the chance of getting specific diseases by identifying genetic predispositions to those ailments or lifestyle variables that may increase risk.¹⁶

Personalized Medicine the Future of Health Care:

Indeed, it is generally acknowledged that customized medicine will play a significant role in healthcare in the future. It signifies a change in perspective toward adjusting medical interventions and therapies to the unique needs of every patient¹⁷. This method recognizes that a person’s health and susceptibility to disease are influenced by their specific genetic composition, lifestyle choices, and environmental circumstances¹⁸.

The revolutionary potential of personalized medicine in increasing preventative measures, optimizing therapeutic techniques, and improving patient outcomes has been emphasized by numerous experts, researchers, and healthcare professionals¹⁹. It is anticipated that customized medicine will become more widely incorporated into standard healthcare procedures as technology develops, especially in areas like genetics, proteomics, and data analytics²⁰. Even if there are obstacles including ethical issues, unequal access, and regulatory frameworks, the general trend indicates that customized medicine will continue to have a big impact on how healthcare is provided in the future²¹.

Challenges and Ethical of Personalized Medicine:

Although personalized medicine, which adapts therapies to each patient’s unique genetic, environmental, and lifestyle characteristics, has enormous promise, it also presents many difficulties and ethical issues. Accessibility is limited, especially in low-income areas, by the high costs of targeted medicines and genome sequencing²². It is difficult to integrate data from various sources (genomics, EHRs, wearables), necessitating interoperability and strong computer systems²³. Personalized medication approval is slowed by regulatory obstacles, and biomarker clinical validation is still uneven²⁴. Privacy is the main ethical concern since genetic Information can be misused by employers or insurers. Patients may not completely comprehend the genomic consequences, which complicates informed consent²⁵. Equity is a big problem; health inequities are made worse by underprivileged populations’ frequent lack of access to sophisticated diagnostics²⁶. Additionally, over-specialized approaches may result in over diagnosis or overtreatment. Lastly, an overemphasis on genetic predispositions, or genetic determinism, may compromise holistic care²⁷. To guarantee that benefits reach all populations, addressing these calls for inclusive research, transparent data governance, and equitable policy²⁸.

Strategies for Prevention:

Preventive measures based on each person’s particular risk factors are another focus of personalized medicine. Healthcare professionals can suggest tailored interventions to lower the chance of getting specific diseases by identifying genetic predispositions to those ailments or lifestyle variables that may raise risk.

Customized Treatment:

By lowering the possibility of negative side effects or treatment resistance, personalized medicine makes it possible to choose therapies based on each patient’s unique likelihood of success²⁹. Patients may experience improved results and a higher quality of life as a result³⁰.

Healthcare professionals can create individualized treatment programs that are more efficient and possibly safer than generic therapies based on this genetic information as well as other variables including lifestyle decisions and environmental exposures³¹. For instance, some cancer treatments can target particular genetic alterations found in a patient’s tumor, improving results and reducing adverse effects³².

Benefits:

delivering benefits to society and healthcare systems.

improving patient care.

Simplifying the process of creating new drugs

Improve the ability to identify illnesses³³.

Reduce the length of time, costs, and failure rate of clinical trials for pharmaceuticals³⁴.

Eliminate the ineffective trial-and-error methods that raise medical costs and jeopardize patient care³⁵.

Application of Personalized Medicine:

These are a few significant uses for personalized medicine. detecting illnesses early on by improved surveillance, which enables more potent therapies or therapeutic choices³⁶.

avoiding generic "one size fits all" prescribing techniques in order to reduce avoidable drug-related problems and side effects³⁷.

maximizing therapeutic efficacy by making sure the right medication is taken and taking into account any genetic variations that can affect how the medicine is metabolized when establishing dosage schedules³⁸.

encouraging and helping people who are at a higher risk of contracting diseases to follow the available preventative measures³⁹.

CONCLUSION:

With personalized medicine, the conventional “one size fits all” approach to healthcare is being replaced by individualized treatment programs that are based on each patient’s particular genetic makeup, lifestyle, and environmental conditions. Healthcare providers can develop individualized treatment plans that are safer and more efficient than generic alternatives by utilizing insights from genomes and other biological data sources. By making it possible to identify disease subtypes and treatment responses that are specific to each patient, the Human Genome Project has significantly advanced the area of personalized medicine. Preventive strategies for people with known genetic predispositions and targeted cancer treatments that target certain genetic abnormalities are examples of personalized medicine applications.

Personalized medicine has many advantages, such as:

Enhanced patient results:

Tailored treatment regimens can result in better health and a higher standard of living. Decreased adverse pharmaceutical reactions: The likelihood of bad reactions can be reduced by customizing treatment based on a patient’s genetic profile.

Enhanced therapeutic efficacy:

By choosing the best drug and dose regimen, personalized medicine can maximize the effectiveness of treatment.

Personalized medicine has the potential to streamline medication development by cutting down on the duration and expense of clinical trials as well as the use of inefficient trial-and-error techniques.

Personalized medicine does, however, come with a number of difficulties and moral dilemmas, such as:

0Equity and accessibility*: Access can be hampered by the high price and restricted supply of targeted medications and genome sequencing, especially in low-income areas. Data privacy and informed consent*: Concerns regarding privacy and informed permission are brought up by the use of genetic data, especially when patients may not fully comprehend.

REFERENCES:

1. Shah GL, Majhail N, Khera N, Giralt S. Value-Based Care in Hematopoietic Cell Transplantation and Cellular Therapy: Challenges and Opportunities. Curr Hematol Malig Rep. 2018 doi: 10.1007/s11899-018-0444-z. [DOI] [PMC free article] [PubMed] [Google

2. Schork NJ. Personalized medicine: Time for one-person trials. Nature. 2015;520(7549):609–11. Doi: 10.1038/520609a.

3. https://pmc.ncbi.nlm.nih.gov/articles/PMC6366451/

4. https://www.genome.gov/genetics-glossary/Personalized-Medicine#:~:text=Personalized%20medicine%20is%20a%20fantastic,that%20kind%20of%20personalized%20approach

5. N.S. Abul-Husn, E.E. Kenny Personalized medicine and the power of electronic health records

6. Suwinski P., Ong C., Ling M.H.T., Poh Y.M., Khan A.M., Ong H.S. Advancing Personalized Medicine through the Application of Whole Exome Sequencing and Big Data Analytics. Front. Genet. 2019; 10:49. Doi: 10.3389/fgene.2019.00049.

7. https://www.sciencedirect.com/science/article/pii/S1098301513018615

8. https://www.medanta.org/patient-education-blog/insights-into-the-future-of-clinical-genetics-advances-and-emerging-technologies#:~:text=Genetic%20sequencing%20helps%20identify%20genetic%20mutations%20that,and%20improving%20our%20ability%20to%20prevent%20diseases

9. Altshuler D, Kruglyak L, Lander E. Genetic polymorphisms and disease. New England Journal of Medicine. 1998;338(22):1626

10. Vogenberg FR, Barash C Isaacson, Pursel M. Personalized medicine: Part 1: Evolution and development into theranostics. P T. 2010; 35:560–576

11. Abul-Husn NS, Owusu OA, Sanderson SC, Gottesman O, Scott SA. Implementation and utilization of genetic testing in personalized medicine. Pharmacogenomics and Personalized Medicine. 2014; 7:227–240. Doi: 10.2147/PGPM.S48887.

12. https://medlineplus.gov/lab-tests/pharmacogenetic-tests/#:~:text=Pharmacogenetic%20testing%20provides%20information%20about,a%20type%20of%20precision%20medicine

13. Washington D.C., The National Academies Press. National Research Council; Washington, DC: 2011. Toward Precision Medicine: Building a Knowledge Network for Biomedical Research and a New Taxonomy of Disease.

14. https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies#:~:text=Targeted%20therapy%20is%20a%20type,Learn%20more%20about%20monoclonal%20antibodies

15. Sairamesh J and Rossbach M: An economic perspective on personalized medicine. HUGO J, 7:12013

16. Check Hayden E. Promising gene therapies pose million-dollar conundrum. Nature. 2016;534(7607):305–6. Doi: 10.1038/534305a.

17. Topol, E. J. High‐performance medicine: the convergence of human and artificial intelligence. Nat. Med. 25, 44–56 (2019).

18. Ozawa, S., Evans, J. P., Kirchhoff, K. T., and Larson, E. B., Pharmacogenomic testing: A systematic review of the economic evidence for its effectiveness on patient outcomes. Personalized Medicine,2018,15(3), 245–257.

19. Suwinski P., Ong C., Ling M.H.T., Poh Y.M., Khan A.M., Ong H.S. Advancing Personalized Medicine through the Application of Whole Exome Sequencing and Big Data Analytics. Front. Genet. 2019; 10:49. Doi: 10.3389/fgene.2019.00049.

20. https://www.mrmed.in/health-library/health-care/personalized-medicine-india

21. Joly Y, Knoppers BM, editors. Routledge Handbook of Medical Law and Ethics. Routledge; New York: 2015. MA: Privacy and Confidentiality; pp. 52–66.

22. Vogenberg FR, Barash C Isaacson and Pursel M: Personalized medicine: Part 1: Evolution and development into theranostics. P T,2010,35,560–576

23. https://www.nrces.in/download/files/pdf/Poster_Standardizing_Genomic_Data.pdf#:~:text=Integrating%20genomic%20data%20into%20Electronic%20Health%20Records,use%20of%20genomic%20information%20in%20clinical%20settings

24. https://www.mdpi.com/1999-4923/16/3/332

25. https://www.ncbi.nlm.nih.gov/books/NBK132157/#:~:text=Genetic%20discrimination.,genetics%20as%20a%20health%20tool

26. Peterson RE, Edwards AC, Bacanu SA, Dick DM, Kendler KS, and Webb BT (2017). The utility of empirically assigning ancestry groups in cross‐population genetic studies of addiction. The American Journal on Addictions, 26(5), 494–501. [DOI] [PMC free article] [PubMed] [Google Scholar

27. Avinun R (2019). Educational Attainment Polygenic Score is Associated with Depressive Symptoms via Socioeconomic Status: A Gene-Environment-Trait Correlation. bioRxiv, 727552.

28. https://www.sciencedirect.com/science/article/pii/S2444569X24001379

29. Abul-Husn N.S., Kenny E.E. Personalized medicine and the power of electronic health records. Cell. 2019; 177:58–69. Doi: 10.1016/j.cell.2019.02.039

30. Wilson I.B., Cleary P.D. Linking clinical variables with health-related quality of life: A conceptual model of patient outcomes. JAMA. 1995; 273:59–65. Doi: 10.1001/jama.1995.03520250075037

31. Alizadeh AA et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403, 503–511 (2000).

32. Rajpurkar P., Chen E., Banerjee O., Topol E.J. AI in health and medicine. Nat. Med. 2022; 28:31–38. Doi: 10.1038/s41591-021-01614-0.

33. https://www.ncbi.nlm.nih.gov/books/NBK2682/

34. Kim, E., Yang, J., Park, S. et al. Factors Affecting Success of New Drug Clinical Trials. Ther Innov Regul Sci 57, 737–750 (2023). https://doi.org/10.1007/s43441-023-00509-1

35. Elliott RA, Camacho E, Jankovic D, et al. Economic analysis of the prevalence and clinical and economic burden of medication error in England. BMJ Qual Saf 2021; 30:96–105. 10.1136/bmjqs-2019-010206

36. Check Hayden E. Promising gene therapies pose million-dollar conundrum. Nature. 2016;534(7607):305–6. Doi: 10.1038/534305a.

37. Shah GL, Majhail N, Khera N, Giralt S. Value-Based Care in Hematopoietic Cell Transplantation and Cellular Therapy: Challenges and Opportunities. Curr Hematol Malig Rep. 2018 doi: 10.1007/s11899-018-0444

38. Arendt D., Musser J.M., Baker C.V.H., Bergman A., Cepko C., Erwin D.H., Pavlicev M., Schlosser G., Widder S., Laubichler M.D., et al. The origin and evolution of cell types. Nat. Rev. Genet. 2016; 17:744–757. Doi: 10.1038/nrg.2016.127. [DOI

39. Eichelbaum M., Ingelman-Sundberg M., Evans W.E. Pharmacogenomics and Individualized Drug Therapy. Annu. Rev. Med. 2006; 57:119–137. Doi: 10.1146/annurev.med.56.082103.104724.

Received on 12.05.2025 Revised on 11.10.2025

Accepted on 23.01.2026 Published on 02.07.2026

Available online from July 15, 2026

Asian J. Res. Pharm. Sci. 2026; 16(3):243-246.

DOI: 10.52711/2231-5659.2026.00036

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Creative Commons License.